Masatoshi Kudo

J-GLOBAL         Last updated: Sep 28, 2016 at 10:10
 
Avatar
Name
Masatoshi Kudo
Nickname
Masatoshi Kudo
E-mail
m-kudomed.kindai.ac.jp
Affiliation
Kindai University
Section
Faculty of Medicine
Research funding number
10298953

Research Areas

 
 

Published Papers

 
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT
Hepatology   64 774-784   2016   [Refereed]
Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan
Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan
Liver Cancer   5 190-197   2016   [Refereed]
Evaluation of anti-migration properties of biliary covered self-expandable metal stents
Minaga K, Kitano M, Imai H, Harwani Y, Yamao K, Kamata K, Miyata T, Omoto S, Kadosaka K, Sakurai T, Nishida N, Kudo M
World J Gastroenterol   22 6917-6924   2016   [Refereed]
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis
Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R
Med Oncol   33 114-121   2016   [Refereed]
Impact of tight junction protein ZO-1 and TWIST expression on post-operative survival of patients with hepatocellular carcinoma
Nagai T, Arao T, Nishio K, Matsumoto K, Hagiwara S, Sakurai T, Minami Y, Ida H, Ueshima K, Nishida N, Sakai K, Saijo N, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Haji S, Kudo M
Digest Dis   34 702-707   2016   [Refereed]
Comparison of two-dimensional shear wave elastography and real-time tissue elastography for assessing liver fibrosis in chronic hepatitis B
Wu T, Wang P, Zhang T, Zheng J, Li JZ, Zeng J, Kudo M, Zheng R
Digest Dis   34 640-649   2016   [Refereed]
Validation of Kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ida H, Sakurai T, Kitano M, Nishida N, Kudo M
Digest Dis   34 671-678   2016   [Refereed]
Comparison of contrast-enhanced ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-enhanced MRI for the diagnosis of macroscopic type of hepatocellular carcinoma
Iwamoto T, Imai Y, Kogita S, Igura T, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Seki Y, Ohashi H, Fujita N, Kudo M, Takehara T
Digest Dis   34 679-686   2016   [Refereed]
Radiofrequency ablation guided by contrast-enhanced sonography versus B-mode sonography for hepatocellular carcinoma after transcatheter arterial chemoembolization
Kawasaki T, Hata K, Kinoshita D, Takayama M, Okuda H, Mizuno S, Kudo M
Digest Dis   34 692-695   2016   [Refereed]
Efficacy and safety of sofosbuvir plus ribavirin treatment for patients with chronic hepatitis C genotype 2
Sugimoto K, Kim SK, Kim SR, Kobayashi M, Kato A, Morimoto E, Imoto S, Kim CW, Tanaka Y, Kudo M, Yano Y, Hayashi Y
Digest Dis   34 627-631   2016   [Refereed]
Prospective risk analysis of hepatocellular carcinoma in patients with chronic hepatitis C by ultrasound strain elastography
Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M
Digest Dis   34 650-653   2016   [Refereed]
Coffee intake and liver enzyme association in Korean immigrants and Japanese: a comprehensive cross-sectional study
Kim SK, Shin MH, Sugimoto K, Kim SR, Imoto S, Kim KI, Taniguchi M, Oh HK, Yano Y, Hayashi T, Kudo M
Digest Dis   34 665-670   2016   [Refereed]
Recent trends in the management of hepatocellular carcinoma with special emphasis on treatment with regorafenib and immune checkpoint inhibitors
Masatoshi Kudo
Digest Dis   34 714-730   2016   [Refereed][Invited]
Prediction of embolization area after conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using SYNAPSE VINCENT
Ogawa C, Minami Y, Morita M, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibatouge M, Kudo M
Digest Dis   34 696-701   2016   [Refereed]
US-US fusion imaging in radiofrequency ablation for liver metastases
Minami Y, Minami T, Chishina H, Kono M, Arizumi T, Takita M, Yada N, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M
Digest Dis   34 687-691   2016   [Refereed]
Clinical significance of epigenetic alterations in human hepatocellular carcinoma and its association with genetic mutations
Nishida N, Kudo M
Digest Dis   34 708-713   2016   [Refereed]
Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis
Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M
Digest Dis   34 659-664   2016   [Refereed]
Monoethanolamine oleate sclerotherapy for polycystic liver disease
Takita M, Iwanishi M, Minami T, Kono M, Chishina K, Arizumi T, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Nishida N, Kudo M
Digest Dis   34 654-658   2016   [Refereed]
Safety, tolerability, and efficacy of sofosbuvir plus rivavirin in elderly patients infected with hepatitis C virus genotype 2
Nishida N, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kudo M
Digest Dis   34 632-639   2016   [Refereed]
Outcome of asunaprevir/daclatasvir combination therapy for chronic liver disease type C
Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M
Digest Dis   34 620-626   2016   [Refereed]
Chronic Liver diseases and liver cancer: state-of-the art progress in 2016
Masatoshi Kudo
Digest Dis   34 617-619   2016   [Refereed][Invited]
EUS-guided gallbladder drainage for rescue treatment of malignant distal biliary obstruction after unsuccessful ERCP
Imai H, Kitano M, Omoto S, Kadosaka K, Kamata K, Miyata T, Yamao K, Sakamoto H, Harwani Y, Kudo M
Gastrointest Endosc   84 147-151   2016   [Refereed]
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladron de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL
Liver Int   36 1196-1205   2016   [Refereed]
Report of the 19th follow-up survey of primary liver cancer in Japan
Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y, and the Liver Cancer Study Group of Japan
Hepatol Res   46 372-390   2016   [Refereed]
Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyi S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ
J Hepatol   65 289-295   2016   [Refereed]
Urgent endoscopic ultrasound-guided choledochoduodenostomy for acute obstructive suppurative cholangitis-induced sepsis
Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Omoto S, Kadosaka K, Yoshikawa T, Kudo M
World J Gastroenterol   22 4264-4269   2016   [Refereed]
New endoscopic ultrasonography techniques for pancreaticobiliary diseases
Kamata K, Kitano M, Omoto S, Kadosaka K, Miyata T, Minaga K, Yamao K, Imai H, Kudo M
Ultrasonography   35 169-179   2016   [Refereed]
Predictors of pain response in patients undergoing EUS - guided neurolysis for abdominal pain caused by pancreatic cancer
Minaga K, Kitano M, Sakamoto H, Miyata T, Imai H, Yamao K, Kamata K, Omoto S, Kadosaka K, Sakurai T, Nishida N, Chiba Y, Kudo M
Ther Adv Gastroenterol   9 483-494   2016   [Refereed]
Response
Kitano M, Imai H, Kamata K, Kudo M
Gastrointest Endosc   83 1303   2016   [Refereed]
Modified single transluminal gateway transcystic multiple drainage technique for a huge infected walled-off pancreatic necrosis: A case report
Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Yoshikawa T, Kudo M
walled-off pancreatic necrosis: A case report.   22 5132-5136   2016   [Refereed]
TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)
Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R
Radiology   279 630-640   2016   [Refereed]
Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial
Kamata K, Kitano M, Yasukawa S, Kudo M, Chiba Y, Ogura T, Higuchi K, Fukutake N, Ashida R, Yamasaki T, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Yanagisawa A
Endoscopy   48 1-7   2016   [Refereed]
Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma
Miyata T, Kitano M, Omoto S, Kadosaka K, Kamata K, Imai H, Sakamoto H, Nishida N, Harwani Y, Murakami T, Takeyamas Y, Chiba Y, Kudo M
World J Gastroenterol   22 3381-3391   2016   [Refereed]
Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B
Masatoshi Kudo
Liver Cancer   5 91-96   2016   [Refereed][Invited]
Kupffer phase image of Sonazoiod-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: A multicenter retrospective study
Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, Tanaka H, Iijima H, Ochi H, Hirooka M, Numata K,Kudo M
J Gastroenterol   51 144-152   2016   [Refereed]
Response evaluation criteria in cancer of the liver (RECICL)(2015 revised version)
Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N, Liver Cancer Study Group of Japan
Hepatol Res   46 3-9   2016   [Refereed]
Multicenter cooperative case survey of hepatitis B Virus reactivation by chemotherapeutic agents
Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M
Hepatol Res   45 1220-1227   2015   [Refereed]
Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration
Yamao K, Kitano M, Kudo M, Maenishi O
Endoscopy   47 596-597   2015   [Refereed]
Antiviral therapy for chronic hepatitis B: combination of nucleoside analogs and interferon
Hagiwara S, Nishida N, Kudo M
World J Hepatol   7 2427-2431   2015   [Refereed]
Recent advances in the management of chronic hepatitis B including suppression of hepatocellular carcinoma by entecavir and interferon
Kim SK, Kim SR, Imoto S, Tohyama M, Otono Y, Tamura T, Kim KI, Kobayashi M, Ohtani A, Sugimoto K, Mizuguchi A, Hiramatsu Y, Kudo M
Oncology   89 60-69   2015   [Refereed]
A newly developed shear wave elastography modality: with a unique reliability index
Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ueshima K, Ida H, Nishida N, Kudo M
Oncology   89 53-59   2015   [Refereed]
Validation of a modified substaging system (Kinki Criteria) for patients with intermediate-stage hepatocellular carcinoma
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, Kudo M
Oncology   89 47-52   2015   [Refereed]
Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma
Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y
Oncology   89 42-46   2015   [Refereed]
Hyperenhanced rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: a histological indication of the presence of Kupffer cells
Tochio H, Sugahara M, Imai Y, Tei H, Suginoshita Y, Iwasaki N, Sasaki I, Hamada M, Minowa K, Inokuma T, Kudo M
Oncology   89 33-41   2015   [Refereed]
Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience
Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Tsurusaki M, Yagyu Y, Ueshima K, Nishida N, Murakami T, Kudo M
Oncology   89 27-32   2015   [Refereed]
Percutaneous radiofrequency ablation for Intermediate-stage hepatocellular carcinoma
Kariyama K, Wakuta A, Nishimura M, Kishida M, Oonishi A, Ohyama A, Nouso K, Kudo M
Oncology   89 19-26   2015   [Refereed]
Initial experience performing percutaneous ultrasound examination with real-time virtual sonography with color display
Ogawa C, Minami Y, Noda T, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Kudo M
Oncology   89 11-18   2015   [Refereed]
Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma
Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M
Oncology   89 4-10   2015   [Refereed]
Evidence and consensus on management of hepatocellular carcinoma: update in 2015
Masatoshi Kudo
Oncology   89 1-3   2015   [Refereed][Invited]
Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma
Nishida N, Kitano M, Sakurai T, Kudo M
Digest Dis   33 771-779   2015   [Refereed]
General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan
Kudo M*, Kitano M, Sakurai T, Nishida N
Digest Dis   33 765-770   2015   [Refereed]
Cone-beam CT angiography for hepatocellular carcinoma: current status
Minami Y, Murakami T, Kitano M, Sakurai T, Nishida N, Kudo M
Digest Dis   33 759-764   2015   [Refereed]
Subclassification of BCLC stage hepatocellular carcinoma and treatment strategies: Proposal of modified Bolondi subclassification (Kinki Criteria)
Kudo M*, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N
Digest Dis   33 751-758   2015   [Refereed]
Hepatic DNA methylation is affected by hepatocellular carcinoma risk in patients with and without hepatitis virus
Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M
Digest Dis   33 745-750   2015   [Refereed]
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis
Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M
Digest Dis   33 728-734   2015   [Refereed]
Characteristics of hypovascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2cm - focus on tumor size, markers and imaging detectability
Sugimoto K, Kim SR, Imoto S, Tohyama M, Kim SK, Matsuoka T, Yano Y, Kudo M, Hayashi Y
Digest Dis   33 721-727   2015   [Refereed]
Usefulness of cytokeratin-18M65 in diagnosing non-alcoholic steatohepatitis in Japanese population
Hasegawa Y, Kim SR, Hatae T, Ohta M, Fujinami A, Sugimoto K, Kim KI, Imoto S, Tohyama M, Kim SK, Ikura Y, Kudo M
Digest Dis   33 715-720   2015   [Refereed]
Early viral response predicts the efficacy of antiviral triple therapy with simeprevir, peg-interferon, and ribavirin in patients infected with hepatitis C virus genotype 1
Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, Kudo M
Digest Dis   33 708-714   2015   [Refereed]
Chronic Liver Diseases and Liver Cancer: An Update in 2015
Masatoshi Kudo
Digest Dis   33 705-707   2015   [Refereed]
Validation of the hepatoma arterial embolisation prognostic score in European and Asian populations and proposed modification
Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, Kudo M, Pirisi M, Sharma R
Clin Gastroenterol H   13 1204-1208   2015   [Refereed]
Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)
Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M
Hepatol Res   45 123-127   2015   [Refereed]
Heat shock protein A4 controls cell migration and gastric ulcer healing
Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, Kudo M
Digest Dis Sci   60 850-857   2015   [Refereed]
The role of hepatic resection in the treatment of hepatocellular cancer
Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts L, Sherman M
Hepatology   62 440-451   2015   [Refereed]
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M
Liver Int   35 2155-2166   2015   [Refereed]
Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy
Masatoshi Kudo
Hepatol Int   9 155-156   2015   [Refereed]
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study
Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M and the investigators’study group
J Hepatol   63 896-904   2015   [Refereed]
Primary leiomyosarcoma of the colon
Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, Kudo M
Clin J Gastroenterol   8 217-222   2015   [Refereed]
Plasmacytoid dendritic cell activation and IFN-α production are prominent features of murine autoimmune pancreatitis and human lgG4-related autoimmune panreatitis
Arai Y, Yamashita K, Kuriyama K, Shiokawa M, Kodama Y, Sakurai T, Mizugishi K, Uchida K, Kadowaki N, Takaori-Kondo A, Kudo M, Okazaki K, Strober W, Chiba T, Watanabe T
J Immunol   195 3033-3044   2015   [Refereed]
Peretinoin after curative therapy of hepatitits C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H, Peretinoin Study Group
J Gastroenterol   50 191-202   2015   [Refereed]
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2; Breast
Barr R, Nakashima K, Amy D, Cosgrove D, Farrokh A, Schafer F, Bamber J, Castera L, Choi B, Chou Y, Dietrich C, Ding H, Ferraioli G, Filice C, Friedrich-Rust M, Hall T, Nightingale K, Palmeri M, Shiina T, Suzuki S, Sporea I, Wilson S, Kudo M
Ultrasound Med Biol   41 1148-1160   2015   [Refereed]
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part3; Liver
Ferraioli G, Filice C, Castera L, Choi B, Sporea I, Wilson S, Cosgrove D, Dietrich C, Amy D, Bamber J, Barr R, Chou Y, Ding H, Farrokh A, Friedrich-Rust M, Hall T, Nakashima K, Nightingale K, Palmeri M, Schafer F, Shiina T, Suzuki S, Kudo M
Ultrasound Med Biol   41 1161-1179   2015   [Refereed]
Foreword to the WFUMB guideline and recommendations on the clinical use of ultrasound elastography
Masatoshi Kudo
Ultrasound Med Biol   41 1125   2015   [Refereed]
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1; basic principles and terminology
Shiina T, Nightingale K, Palmeri M, Hall T, Bamber J, Barr R, Castera L, Choi B, Chou Y, Cosgrove D, Dietrich C, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M
Ultrasound Med Biol   41 1126-1147   2015   [Refereed]
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized placebo-controlled trial
Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H, and Peretinoin Study Group
J Gastroenterol   50 667-674   2015   [Refereed]
Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliaty diseases
Kitano M, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, Kudo M
Digest Endosc   27 60-67   2015   [Refereed]
A bridge between multi-omics data and the management of hepatocellular carcinoma
Nishida N, Kudo M
Ann Transl Med   3 1   2015   [Refereed]
Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection
Okumura N, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Kawasaki M, Tomita T, Umehara Y, Taniike S, Kono M, Kudo M
Gastroenterol Rep   3 69-74   2015   [Refereed]
Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, Nowiem SE
J Clin Oncol   33 172-179   2015   [Refereed]
Stabilization technique for real-time high-resolution vascular ultrasound using frequency domain interferometry
Taki H, Taki K, Yamakawa M, Shiina T, Kudo M, Sato T
Conf Proc IEEE Eng Med Biol Soc   5085-5088   2014   [Refereed]
Malignant transformation of hepatocellular adenoma: How frequently does it happen?
Masatoshi Kudo
Liver Cancer   1 1-5   2015   [Refereed]
Involvement of heat shock protein A4/Apg-2 in refractory inflammatory bowel disease
Adachi T, Sakurai T, Kashida H, Mine H, Hagiwara S, Matsui S, Yoshida K, Nishida N, Watanabe T, Itoh K, Fujita J, Kudo M
Inflamm Bowel Dis   21 31-39   2015   [Refereed]
Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic Masses
Ashida R, Yasukawa S, Yanagisawa A, Kamata K, Kudo M, Ogura T, Higuchi K, Fukutake N, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Kitano M
Gastrointest Endosc   79 AB111   May 2014   [Refereed]
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, FuruseJ, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ
Int J Clin Pract   68(5) 609-617   May 2014   [Refereed]
Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Three-Dimensional Cone-Beam CT Angiography
Minami Y, Yagyu Y, Murakami T, Kudo M
Liver Cancer   3(1) 53-61   Mar 2014   [Refereed]
Therapeutic Response Assessment of RFA for HCC: Contrast-enhanced US, CT and MRI
Minami Y, Nishida N, Kudo M
World J Gastroenterol   20 4160-4166   Apr 2014   [Refereed]
Reply to Kadayifci and brugge
Kitano K, Kamata K, Kudo M
Endoscopy   46 358-358   Apr 2014
Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy
Kawanaka M, Nishio K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G
Liver Cancer   3(1) 41-52   Mar 2014   [Refereed]
Relevance of the core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a± ribavirin for chronic hepatitis C of genotype 1b: A multicenter randomized trial, ReGIT-J study
Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M
J Gastroenterol   49 492-501   Mar 2014   [Refereed]
Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel
Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW
Liver Int   34(2) 174-183   Feb 2014   [Refereed]
Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M for the Liver Cancer Study Group of Japan
Ann Surg   259(2) 336-345   Feb 2014   [Refereed]
The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US
Hatanaka K, Minami Y, Kudo M*, Inoue T, Chung H, Haji S
J Clin Ultrasound   42(1) 1-8   Jan 2014   [Refereed]
Impact of histologically confirmed lymph node metastases on the patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey
Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima M, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan
Ann Surg   259 166-170   Jan 2014   [Refereed]
Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y
Endoscopy   46(1) 22-29   Jan 2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
Arizumi T, Ueshima K, Takeda H, Osaki Y, Takita M, Inoue T, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M
J Gastroenterol   49 1578-1587   2014   [Refereed]
NOD2 Down-regulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6
Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, Kudo M, Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W
Mucosal Immunol   7 1312-1325   2014   [Refereed]
Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer
Sakurai T, Kashida H, Watanabe T, Hagiwara S, Mizushima T, Iijima H, Nishida N, Higashitsuji H, Fujita J, Kudo M
Cancer Res   74 6119-6128   2014   [Refereed]
Dynamic changes of the inflammation based index (IBI) predict mortality following chemoembolization for hepatocellular carcinoma: a prospective study
Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Kudo M, Jang JW, Sharma R
Aliment Pharm Ther   40 1270-1281   2014   [Refereed]
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase 3 trial
Kudo M*, Han G, Finn RS, Poon RTP, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Cruz CD, poulart V, Wang JH
Hepatology   60 1697-1707   2014   [Refereed]
Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study
Wu T, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ
Digest Dis   32 791-799   2014   [Refereed]
Clinical features of vascular disorders associated with chronic hepatitis virus infection
Nishida N, Kudo M
Digest Dis   32 786-790   2014   [Refereed]

Misc

 
KUDO Masatoshi
109(8) 1327-1334   Aug 2012
ARIZUMI Tadaaki, UESHIMA Kazuomi, TAKEDA Haruhiko, OSAKI Yukio, HAGIWARA Satoru, INOUE Tatsuo, KITAI Satoshi, YADA Norihisa, SAKURAI Toshiharu, NISHIDA Naoshi, KUDO Masatoshi
Kanzo   53(6) 344-347   Jun 2012
Response Evaluation Criteria In Solid Tumor version 1.1 (RECIST1.1), modified RECIST (mRECIST) and Response Evaluation Criteria In Cancer of the Liver (RECICL) are frequently used as a response evaluation criteria for hepatocellular carcinoma. The...
ARIZUMI Tadaaki, UESHIMA Kazuomi, HAYAISHI Sousuke, TAKITA Masahiro, KITAI Satoshi, INOUE Tatsuo, YADA Norihisa, HAGIWARA Satoru, MINAMI Yasunori, SAKURAI Toshiharu, NISHIDA Naoshi, KUDO Masatoshi
Kanzo   53(6) 348-350   Jun 2012
【PURPOSE】 Sorafenib is a molecularly-targeted drug, which have been proven survival benefit for advanced hepatocellular carcinoma (HCC). Because of the unique side effects of sorafenib such as hand-foot skin reaction (HFSR), the administration of ...
INUZUKA Tadashi, OSAKI Yukio, MATSUDA Fumihiro, SAKAMOTO Azusa, HATAMARU Keiichi, HENMI Shinichiro, ISHIKAWA Tetsuro, SAITO Sumio, NISHIKAWA Hiroki, KITA Ryuichi, OKABE Yoshihiro, KIMURA Toru, WAKASA Tomoko, HAGIWARA Satoru, KUDO Masatoshi
Kanzo   53(1) 42-47   Jan 2012
A 65-year-old Japanese male with chronic hepatitis B (CH-B) diagnosed in December 2008 was referred to our department in July 2009. He started combination therapy with peginterferon alfa-2b (80 μg/week) and entecavir (0.5 mg/day) for 48 weeks from...
KUDO Masatoshi
Nippon Shokakibyo Gakkai Zasshi   109(8) 1327-1334   2012

Books etc

 
Liver Cancer, Okuda K and Tabor E, eds, Ultrasound Diagnosis
Churchill Livingstone, London   1997   
"Diagnosis and Treatment of Hepatocellular Carcinoma", Livraghi T, Makuuchi M, Buscarini, eds, Scintigraphy
Greenwich Medical Media Limited, London, UK   1997   
"Hepatology in the 21st Century: Diagnosis and Therapy." Tanikawa K, Kojiro M, Gollan J, eds, Advances in diagnostic imaging of hepatocellular carcinoma
IASL, APASL, and JSH JOINT POST GRADUATE TEXTBOOK, IASL Publ, Fukuoka   2000   
In Dynamic Study of Efferent Tumor Blood Fow, Itai Y, Miura Y, eds, Color Doppler observation of efferent blood flow in liver tumors
BRACCO, Italy   2000   

Conference Activities & Talks

 
Combination therapy with peginterferon and entecavir for persistent viral suppression in patients with chronic hepatitis B
Hagiwara S, Nishida N, Kudo M
23rd International Symposium on Hepatitis C Virus and Related Viruses (HCV2016)   13 Oct 2016   
chair; The position of molecular target therapy in HCC, now and future [Invited]
Masatoshi Kudo
12th Japan Society of Hepatology   23 Sep 2016   
Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma
Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Arai Y, Kanai F, Akazawa K
10th Annual Conference International Liver Cancer Association (ILCA)   11 Sep 2016   
Patients benefit from treatment with sorafenib for more than 28 weeks: analysis from the GIDEON study according to duration of treatment
Ye SL, Lencioni R, Nakajima K, Kudo M
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
Validation of a proposed substaging system for patients with intermediate hepatocellular carcinoma
Arizumi T, Ueshima K, Kudo M
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
New technology to detect of tumor-feeding branches and simulate embolization area of hepatocellular carcinoma with SYNAPSE VINCENT durint transcatheter arterial chemoembolization
Ogawa C, Shibatoge M, Kudo M
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu AX, Galle PR, Kudo M, Finn RF, Yang L, Abada PB, Llovet JM
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS interim analysis
Cheng AL, Raoul JL, Lee HC, Kudo M, Nakajima K, Peck-Radosavljevic M on behalf of the OPTIMIS Investigators
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
A propensity score analysis on survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion using nationwide survey data in Japan
Kokudo N, Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Izumi N
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
Safety and antitumour activity of Nivolumab (Nivo) in patients with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 checkmate-040 study
Sangro B, Melero I, Yau T, Hsu C, Kudo M, Crocenzi T, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J, dela Cruz C, Lang L, Neely J, El-Khoueiry A
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
New subclassification of intermediate stage HCC: Analysis of 46,997 Japanese HCC patients from a nationwide survey of the Liver Cancer Study Group of Japan
Ueshima K, Kudo M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kokudo N, Takayama T, Sakamoto M, Nakashima O, Matsuyama Y
10th Annual Conference International Liver Cancer Association (ILCA)   10 Sep 2016   
Chair: ILCA Symposium 2 “Controversies in Liver Cancer” [Invited]
Masatoshi Kudo
ILCA 10th Annual Conference 2016   9 Sep 2016   
Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma” [Invited]
Masatoshi Kudo
14th Annual Meeting of the Japanese Society of Medical Oncology   30 Jul 2016   
Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma” [Invited]
Masatoshi Kudo
14th Annual Meeting of the Japanese Society of Medical Oncology   29 Jul 2016   
Chair; Poster Session “Hepatoma/HCC, Biliary Tract Cancer” [Invited]
Masatoshi Kudo
14th Annual Meeting of the Japanese Society of Medical Oncology   28 Jul 2016   
Special Lecture “Role of EOB-MRI in the management of HCC” [Invited]
Masatoshi Kudo
Bayer Sponsored Meeting From Diagnosis to Treatment, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   10 Jul 2016   
Chair; Session 17: State-of-the Art Lecture “Systemic Therapy for HCC – The Future and Beyond” [Invited]
Masatoshi Kudo
The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   10 Jul 2016   
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line Sorafenib (REACH-2)
Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada PB, Llovet JM
7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   9 Jul 2016   
Chair; Session 14: Debate Session [Invited]
Masatoshi Kudo
The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   9 Jul 2016   
Chair; Consensus Workshop2 “Role of Chemotherapy in HCC” [Invited]
Masatoshi Kudo
The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   9 Jul 2016   
Easy detection of tumor-feeding branches of hepatocellular carcinoma with SYNAPSE VINCENT during transcatheter arterial chemoembolization
Ogawa C, Shibatoge M, Kudo M
7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   8 Jul 2016   
Safety and antitumor activity of Nivolumab (Nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the Phase 1/2 CheckMate-040 study
Sangro B, Melero I, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J, dela Cruz C, Lang L, Neely J, El-Khoueiry AB
7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   8 Jul 2016   
State-of-the Art Lecture “Recent Advancement in HCC Treatment” [Invited]
Masatoshi Kudo
7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   8 Jul 2016   
Chair; Consensus Workshop2 “Role of Chemotherapy in HCC” [Invited]
Masatoshi Kudo
The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   8 Jul 2016   
“Proposal of new BCLC stage B subclassification”, Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC” [Invited]
Masatoshi Kudo
52nd Annual Meeting of Liver Cancer Study Group of Japan   1 Jul 2016   
Chair: Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC” [Invited]
Masatoshi Kudo
1 Jul 2016   
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
Abou-Alfa GK, Sangro B, Morse M, Zhu AX, Kim RD, Cheng AL, Kudo M, Kang YK, Chan SL, Antal J, Boice J, Xiao F, Morris SR, Bendell J, 022 Study Group
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   5 Jun 2016   
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   4 Jun 2016   
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu AX, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Llovet JM
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   4 Jun 2016   
Safety and antitumor activity of Nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study
Sangro B, Melero I, Yau TC, Hsu C, Kudo M, Crocenzi TS, Kim TY, Choo SP, Trojan J, Meyer T, Kang YK, Anderson J、Dela Cruz C, Lang L, Neely J, El-Khoueiry AB
52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)   4 Jun 2016   
Usefulness of contrast-ehnaced ultrasonography with sonazoid in the preperative evaluation of histological differentiation and gross types of hepatocellular carcinoma
Ogawa C, Minami Y, Kudo M
8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201   29 May 2016   
EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」
Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Kudo M
日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)   28 May 2016   
Utility of endoscopic ultrasonography for follow-up of IPMN. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」
Kamata K, Kitano M, Kudo M
日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)   28 May 2016   
US-US image fusion in radiofrequency ablation therapy for hepatocellular carcinoma [Invited]
Minami Y, Minami T, Kudo M
8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201   27 May 2016   
New US technology using 3D volume analyzer synapse VINCENT [Invited]
Ogawa C, Minami Y, Kudo M
8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201   27 May 2016   
Contrast-enhanced harmonic EUS for pancreatic diseases [Invited]
Kitano M, Kamata K, Omoto S, Minaga K, Yamao K, Imai H, Takenaka M, Kudo M
8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201   26 May 2016   
An objective model to optimize treatment decisions in advanced hepatocellular carcinoma after sorafenib failure: the SORFA score
Pinato DJ, Yen C, Arizumi T, Giarda P, Howell J, Ramaswami R, Burlone ME, Kudo M, Pirisi M, Sharma R
The International Liver Congress 2016   16 Apr 2016   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH patients by albumin-bilirubin (ALBI) grade
Blanc JF, Chan SL, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Baran A, Pfiffer T, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Abada P, Chang SC, Yang L, Zhu A
The International Liver Congress 2016   16 Apr 2016   
Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatine/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma
Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Arai Y, Kanai F, Akazawa K, and SILIUS Study Group
The International Liver Congress 2016   16 Apr 2016   
Invited Lecture “Hepatocellular cancer drug development” [Invited]
Masatoshi Kudo
8th Annual Asian Oncology Summit (AOS 2016)   4 Mar 2016   
Practice patterns, sorafenib dosing and safety in Asian hepatocellular carcinoma patients in GIDEON
Kudo M, Venook A, Lencioni R, Ye SL, Nakajima K, Marrero J
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Regional differences in practice patterns among countries, Luncheon Symposium “New light on the integration of evidence into practice” [Invited]
Masatoshi Kudo
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Biomarker and Imaging Diagnosis of HCC. Symposium 11 “Update of HCC Treatment”
Masatoshi Kudo
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Invited Lecture “Non-Curative Treatment (TACE/Sorafenib) of HCC” [Invited]
Masatoshi Kudo
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Regional Differences in the Use of Transarterial Chemoembolization (TACE) in HCC: Interim Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib After TACE
Lee HC, Cheng AL, Raoul JL, Peck-Radosavljevic M, Nakajima K, Kudo M, on behalf of the OPTIMIS Investigators
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)   23 Feb 2016   
Invited Lecture “Immuno-oncology for HCC: Beyond the target therapy” [Invited]
Masatoshi Kudo
the 1st anniversary International Symposium of Yonsei Liver Center   19 Feb 2016   
Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC)
Masatoshi Kudo
American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)   22 Jan 2016   
Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial
Kudo M, Okusaka T, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M
American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)   22 Jan 2016   
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu A, Galle PR, Kudo M, Finn RS, Yang L, Abada P, Chang SC, Llovet JM
American Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)   22 Jan 2016   
Usefulness of serum procalcitonin for diagnosis of acute pancreatitis
Omoto S, Kitano M, Sakamoto H, Imai H, Yamao K, Kamata K, Miyata T, Minaga K, Kadosaka K, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
The analysis of three cases that gastrointestinal bezoars have history of gastrointestinal surgery
Okamoto K, Matsui S, Tanaka R, Yamada M, Adachi T, Takayama M, Mine H, Nagai T, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Kashida H, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
Treatment of colorectal LST: focus on EMR techniques
Komeda Y, Kashida H, Sakurai T, Asakuma Y, Okazaki Y, Nagai T, Mine H, Adachi T, Tanaka R, Yamada M, Kono M, Okamoto K, Matsui S, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
A case of endoscopic mucosal resection for gastric perineurioma
Kono M, Matsui S, Okamoto K, Yamada M, Tanaka R, Adachi T, Mine H, Nagai T, Okazaki Y, Komeda Y, Asakuma Y, Sakurai T, Kashida H, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR (EMR)
Yamada M, Kashida H, Komeda Y, Okamoto K, Kono M, Tanaka R, Adachi T, Mine H, Nagai T, Okazaki Y, Asakuma Y, Sakurai T, Matsui S, Kudo M
Asian Pacific Digestive Week (APDW 2016)   3 Dec 2015   
Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinoma
Nishida N, Kaido T, Kudo M
66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015)   17 Nov 2015   
PALBI-an objective score based on platelets, albumin & Bilirubin Stratifies HCC patients undergoing resection & ablation better than Child’s classification
Roayaie S, Jibara G, Berhane S, Tabrizian P, Park JW, Yang J, Yan L, Han G, Izzo F, Chen M, Blanc JF, Kudo M, Roberts LR, Sherman M, Johnson P
66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015)   14 Nov 2015   
Predictive factors for outcomes of through-the-scope gastroduodenal stenting in patients with gastric outlet obstruction; a large multicenter retrospective study in West Japan
Yamao K, Kitano M, Kayahara T, Ishida E, Minaga K, Yamashita Y, Nakajima J, Asada M, Okabe S, Chiba Y, Imai H, Kudo M
23rd United European Gastroenterology Week (UEGW 2015)   27 Oct 2015   
Evaluation of anti-migration properties of biliary covered self-expandable metal stents
Minaga K, Kitano M, Harwani Y, Imai H, Kamata K, Miyata T, Yamao K, Kadosaka K, Omoto S, Kudo M
23rd United European Gastroenterology Week (UEGW 2015)   26 Oct 2015   
Invited Lecture “Ultrasound fusion imaging of liver tumor: recent progress and clinical relevance” [Invited]
Masatoshi Kudo
IEEE International Ultrasonics Symposium   23 Oct 2015   
EUS guided biliary drainage for treatment of biliary obstruction. International Session (Panel Discussion) 2 “Strategy of treatment for biliary stenosis”
Imai H, Kitano M, Kudo M
第90回日本消化器内視鏡学会総会   10 Oct 2015   
Discussant, International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy” [Invited]
Masatoshi Kudo
8 Oct 2015   
Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma. International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”
Nishida N, Kudo M
8 Oct 2015   
Invited Lecture “Hepatologists’ perspectives on EOB-MRI: Pre-& post-operative evaluation in malignant lesions” [Invited]
Masatoshi Kudo
Asila Pacific Liver Imaging Symposium (APLIS)   17 Sep 2015   
Invited Lecture; Luncheon Satellite Symposium “Treatment strategies to optimize outcome and experience of patients with HCC” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
KLCSG & LCSGJ Joint Symposium “HCC nationwide surveillance and out come in Japan” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
Special Lecture 2”The evolution of HCC treatment” [Invited]
Masatoshi Kudo
The Liver Week 2015   11 Sep 2015   
Chair: General Session 2 “Molecular Pathogenesis of Liver Cancer II” [Invited]
Masatoshi Kudo
International Liver Cancer Association 9th Annual Conference (ILCA) 2015   4 Sep 2015   
Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized Phase III REACH study: analysis ofα-fetoprotein (AFP) kinetics during treatment
Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Eduardo T, Pfiffer F, Hatano E, Chung HC, Kubackova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Yang L, Abada PB, Zhu AX
European Cancer Congress 2015 (18th ECCO-40th ESMO)   Sep 2015   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the phase III REACH trial.
Kudo M, Hatano E, Okusaka T, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Arai K, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Asou H, Abada PB, Yang L, Zhu AX
9th Annual Conference International Liver Cancer Association (ILCA)   Sep 2015   
Invited Lecture “Assessing treatment effect and treatment failure: when to stop LRTs” [Invited]
Masatoshi Kudo
9th Annual Conference International Liver Cancer Association (ILCA)   Sep 2015   
State of Art Lecture “Benefit of early diagnosis of liver cancer with changed therapeutic paradigm in HCC” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   2 Aug 2015   
Invited Lecture “Imaging in early HCC-MR advances” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   1 Aug 2015   
Invited Lecture“HCC: early diagnosis impacts prognosis” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   31 Jul 2015   
Invited Lecture“Molecular targeted therapy for HCC: current status and future perspectives” [Invited]
Masatoshi Kudo
23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)   31 Jul 2015   
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
Ohkawa S, Okusaka T, Kudo M, Hatano E, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Arai K, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Asou H, Abada PB, Yang L, Zhu AX
The 13th Annual Meeting of Japanese Soceity of Medical Oncology   17 Jul 2015   
Activin signal in pancreatic cancer
Togashi Y, Sakamoto H, Kogita A, de Velasco M, Sakai K, Fujita Y, Tomida S, Kitano M, Kudo M, Nishio K
The 13th Annual Meeting of Japanese Soceity of Medical Oncology   17 Jul 2015   
Chair "Poster Session: Biliary Tract and Pancreatic Cancer 2 FOLFIRINOX(2)" [Invited]
Masatoshi Kudo
The 13th Annual Meeting of Japanese Society of Medical Oncology   16 Jul 2015   
Moderator and Commentator “Non-surgical treatment of HCC: achievement from Taiwan over the past quarter century” [Invited]
Masatoshi Kudo
Taiwan Association for the Study of the Liver 2015 (TASL)   12 Jul 2015   
Moderator and Commentator “Androgen pathway in the mechanisms of liver carcinogenesis and targets for future therapy” [Invited]
Masatoshi Kudo
Taiwan Association for the Study of the Liver 2015 (TASL)   12 Jul 2015   
Chari: Sponsored Seminar“Diagnostic Imaging with EOB-MRI for Malignancy Grade of HCC” [Invited]
Masatoshi Kudo
The 6th Asia-Pacific Primary Liver Cancer Expert Meeting   3 Jul 2015   
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score
Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone C, Okusaka T, Wada Y, Park J, Ryoo B, Cho JY, Chung HC, Li C, Yen C, Lee K, Yang L, Chau I
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study
Llovet JM, Park J, Torres F, Decaens T, Boucher E, Raoul J, Kudo M, Chang C, Boige V, Assenat E, Kang Y, Lim H, Walters I, Lencioni R
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz J, Park J, Ryoo B, Yen C, Kudo M, Poon RT, Pastorelli D, Blanc J, Chung H, Baron AD, Okusaka T, Cui ZL, Girvan AC, Abada P, Yang L, Zhu AX
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial
Ikeda M, Shimizu S, Sato T, Morimoto M, Inaba Y, Kojima Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan
Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, The Liver Cancer Study Group of Japan
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib refractory advanced hepatocellular carcinoma (S-CUBE)
Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Okusaka T
Annual Meeting of American Society of Clinical Oncology (ASCO 2015)   1 Jun 2015   
Invited Lecture “HCC nationwide surveillance and outcome in Japan” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
Invited Lecture “The evolution of HCC treatment” [Invited]
Masatoshi Kudo
The Liver Week 2015   11 Sep 2015   
Chairs: “KLCSG & JLCSG Joint Symposium” [Invited]
Masatoshi Kudo
The Liver Week 2015   12 Sep 2015   
Contrast-enhanced harmonic EUS for differential diagnosis of pancreatic tumors. International Video Session 2 “Advances and education of endoscopic diagnosis and treatment-biliary tract, pancreas-“
Kamata K, Kitano M, Kudo M
第89回日本消化器内視鏡学会総会   29 May 2015   
An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS
Peck-Radosavljevic M, Raoul JL, Lee HC, Kudo M, Nakajima K, Cheng AL
50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015)   24 Apr 2015   
Combined sequential use of HAP and ART scores to predict transarterial chemoembolization failure in hepatocellular carcinoma: a multicenter comparative study
Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah P, Smirne C, Grossi G, Pirisi M, Kudo M, Sharma R
50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015)   24 Apr 2015   
Invited Lecture “Surveillance, treatment and outcome of HCC in Japan” [Invited]
Masatoshi Kudo
Joint Workshop EASL-JSH, 50th International Liver Congress of the European Association for the Study of the Liver (EASL)   25 Apr 2015   
GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib): A retrospective analysis of prognostic factors for survival
Bronowicki JP, Kudo M, Lencioni R, Chen XP, Dagher L, Furuse J, Geschwind JFH, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Ye SL, Marrero JA
50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015)   24 Apr 2015   
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer
Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Kudo M, Nishio K
American Association for Cancer Research Annual Meeting (AACR 2015)   21 Apr 2015   
Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer
Kang YK, Seery TE, Kato M, Chakrabarti D, Valota O, Chen Y, Jie T, Pithavala Y, Kudo M
American Association for Cancer Research Annual Meeting (AACR 2015)   19 Apr 2015   
Invited Lecture “WFUMB Guidelines” [Invited]
Masatoshi Kudo
American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015)   21 Mar 2015   
Invited Lecture “Liver strain” [Invited]
Masatoshi Kudo
American Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015)   21 Mar 2015   
Multicenter Observational Study of Reactivation of Hepatitis B Virus Caused by Chemotherapy with Sorafenib
Furuse J, Ikeda M, Kondo S, Kudo M, Nadano S, Osaki Y, Kumada T, Ohkawa K, Mizokami M
24th Conference of APASL   14 Mar 2015   
Multicenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors
Furuse J, Ikeda M, Kondo S, Kudo M, Nadano S, Osaki Y, Kumada T, Ohkawa K, Mizokami M
24th Conference of APASL   14 Mar 2015